About ALOXI®
FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV)
PATIENTS NEED MORE COMPLETE PREVENTION
ALOXI offered better overall prevention of CINV than ondansetron/dolasetron in phase III clinical trials. 1-3
*ALOXI (palonosetron HCl) injection 0.25 mg is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy, and acute nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy.
ALOXI is contraindicated in patients known to have hypersensitivity to the drug or any of its components. It should be administered with caution in patients who have or may develop prolongation of cardiac conduction intervals, particularly QTc. Most commonly reported adverse reactions include headache (9%) and constipation (5%).
References
- Gralla R, Lichinitser M, Van der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol, 2003;14:1570-1577.
- Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003;98:2473-2482.
- Rubenstein EB, Gralla RJ, Eisenberg P, et al. Palonosetron (PALO) compared with Ondansetron (OND) or dolasetron (DOL) for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV): combined results of two phase II trials. Proc Am Soc Clin Oncol. 2003;22:729.
- ALOXI (palonosetron HCI) injection full prescribing information.
- Anzemet® (dolasetron mesylate) full prescribing information.
- Zofran® (Ondansetron hydrochloride) full prescribing information.
- Kytril® (granisetron hydrochloride) full prescribing information.
- Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. 2004;100:2261-2268.
During initial and repeat courses of chemotherapy, ALOXI helps prevent and control nausea and vomiting the day following chemotherapy that is highly likely to cause nausea and vomiting, and for up to 5 days following chemotherapy that is likely to cause nausea and vomiting.
The most frequent side effects of ALOXI include headache and constipation. If you have or may develop significant heart rhythm changes, talk with your healthcare professional before receiving ALOXI.
ALOXI is available by prescription only. Please see the important product information for ALOXI for more information.
This site does not contain everything that is known about ALOXI. If you would like to know more, talk to your healthcare professional.
Kytril® is a registered trademark of Roche Laboratories Inc.
Zofran® is a registered trademark of GlaxoSmithKline.
Anzemet® is a registered trademark of Sanofi-Aventis.